Finance

Lists
Why is RPGLIFE down 2,17%?
Dive Deeper
RPGLIFE:NSE
RPG Life Sciences Ltd
2 830,00 INR
-2,17%
(-62,80) 1D
8 ოქტ, 15:30:01 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for RPGLIFE...
Open
2 892,80 INR
High
2 912,00 INR
Low
2 795,00 INR
Mkt. cap
46,76 მლრდ.
Avg. vol.
31,87 ათ.
Volume
15,87 ათ.
Dividend
0,85%
Quarterly dividend
6,00 INR
Ex-dividend date
9 ივლ. 2026
P/E ratio
39,12
52-wk high
3 127,80 INR
52-wk low
1 733,00 INR
EPS
72,34 INR
Shares outstanding
16,54 მლნ.
No. of employees
1 ათ.
Open
2 892,80 INR
High
2 912,00 INR
Low
2 795,00 INR
Mkt. cap
46,76 მლრდ.
Avg. vol.
31,87 ათ.
Volume
15,87 ათ.
Dividend
0,85%
Quarterly dividend
6,00 INR
Ex-dividend date
9 ივლ. 2026
P/E ratio
39,12
52-wk high
3 127,80 INR
52-wk low
1 733,00 INR
EPS
72,34 INR
Shares outstanding
16,54 მლნ.
No. of employees
1 ათ.
News stories
From web sources and news partners
Profile
RPG Life Sciences is an Indian pharmaceutical company. Formerly known as Searle Ltd, RPG Life Sciences is part of RPG Enterprises. It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as active pharmaceutical ingredients; pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries. Wikipedia
About RPG Life Sciences Ltd
CEO-
Employees1,37 ათ.
Founded1993
Headquarters-
SectorPharmaceutical industry
Last report
28 ივლ. 2026
Fiscal period
Q1 2027
- / -
Revenue / Est. (INR)
1,96 მლრდ. / -
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,82 მლრდ.
1,80 მლრდ.
1,77 მლრდ.
1,96 მლრდ.
Cost of goods sold
665,80 მლნ.
649,00 მლნ.
661,00 მლნ.
681,50 მლნ.
Cost of revenue
665,80 მლნ.
649,00 მლნ.
661,00 მლნ.
681,50 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
361,60 მლნ.
353,20 მლნ.
570,90 მლნ.
377,60 მლნ.
Operating expense
812,90 მლნ.
807,50 მლნ.
835,00 მლნ.
901,50 მლნ.
Total operating expenses
1,48 მლრდ.
1,46 მლრდ.
1,50 მლრდ.
1,58 მლრდ.
Operating income
338,10 მლნ.
343,80 მლნ.
273,30 მლნ.
373,90 მლნ.
Other non operating income
45,40 მლნ.
34,10 მლნ.
-101,90 მლნ.
47,00 მლნ.
EBT including unusual items
494,50 მლნ.
291,20 მლნ.
402,00 მლნ.
414,60 მლნ.
EBT excluding unusual items
382,30 მლნ.
375,40 მლნ.
277,30 მლნ.
414,60 მლნ.
Income tax expense
126,00 მლნ.
69,90 მლნ.
103,00 მლნ.
107,00 მლნ.
Effective tax rate
25,48%
24,00%
25,62%
25,81%
Other operating expenses
399,10 მლნ.
400,50 მლნ.
206,70 მლნ.
464,90 მლნ.
Net income
368,50 მლნ.
221,30 მლნ.
299,00 მლნ.
307,60 მლნ.
Net profit margin
20,28%
12,29%
16,90%
15,72%
Earnings per share
-
-
-
-
Interest and investment income
-
-
96,70 მლნ.
-
Interest expense
-1,20 მლნ.
-2,50 მლნ.
-3,90 მლნ.
-6,30 მლნ.
Net interest expenses
-1,20 მლნ.
-2,50 მლნ.
92,80 მლნ.
-6,30 მლნ.
Depreciation and amortization charges
52,20 მლნ.
53,80 მლნ.
57,40 მლნ.
59,00 მლნ.
EBITDA
389,90 მლნ.
395,75 მლნ.
325,80 მლნ.
426,40 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები